Get the Stockscreener App
4.62
3.14%
-0.15
After Hours:
4.60
-0.02
-0.43%
Vyome Holdings Inc stock is traded at $4.62, with a volume of 20,374.
It is down -3.14% in the last 24 hours and down -13.16% over the past month.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.
See More
Previous Close:
$4.77
Open:
$4.7525
24h Volume:
20,374
Relative Volume:
0.07
Market Cap:
$26.08M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-7.78%
1M Performance:
-13.16%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$4.62
$4.878
1-Week Range:
$4.62
$5.88
52-Week Range:
$4.44
$12.87
Vyome Holdings Inc Stock (HIND) Company Profile
Name
Vyome Holdings Inc
Sector
Industry
Phone
949-429-6680
Address
1001 CALLE AMANECER, SAN CLEMENTE
Compare HIND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HIND
Vyome Holdings Inc
|
4.62 | 26.92M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vyome Holdings Inc Stock (HIND) Latest News
Vyome Holdings announces VT-1953 trial achieves primary, secondary endpoints - MSN
Check Out Vyome Holdings Inc (HIND)’s Trade Data Rather Than the Analysts’ Views - setenews.com
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval - BioSpace
Vyome stock soars after malodor treatment shows positive results - Investing.com
Vyome stock soars after malodor treatment shows positive results By Investing.com - Investing.com UK
Vyome reports positive final Phase 2 results for VT-1953, plans to advance into pivotal study for FDA approval - marketscreener.com
HIND Stock Price and Chart — NASDAQ:HIND - TradingView
Vyome Holdings (HIND) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
JOLLY MOHANJIT Insider Trades - Nasdaq
Vyome Holdings, Inc. (HIND) Recent Insider Transactions - Yahoo! Finance Canada
Vyome Holdings, Inc. (HIND) recent insider transactions - Yahoo Finance UK
Vyome Holdings, Inc. (HIND) Profit Margin (Quarterly) - Zacks Investment Research
Vyome Holdings files prospectus related to resale of 610,185 shares of common stock by selling stockholders - marketscreener.com
Vyome Holdings Files Prospectus Related To Resale Of 610,185 Shares Of Common Stock By Selling Stockholders - TradingView
Vyome Holdings Inc. Reports Post-Merger Financials - MSN
Vyome taps Dr. Bardia as senior medical advisor for wound treatment - Investing.com Nigeria
Vyome Appoints Dr. Aditya Bardia as Senior Medical Advisor - citybiz
Vyome taps Dr. Bardia as senior medical advisor for wound treatment By Investing.com - Investing.com South Africa
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program - Yahoo Finance
Earnings call transcript: Vyome Holdings Q3 2025 sees strategic advancements - Investing.com Nigeria
Vyome Therapeutics2025 Latest Shareholding - Tracxn
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing - Bluefield Daily Telegraph
Vyome Holdings Inc. (HIND) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vyome Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
HIND Forecast — Price Target — Prediction for 2026 - TradingView
Critical Contrast: Vyome (NASDAQ:HIND) vs. TranS1 (OTCMKTS:BAXSQ) - Defense World
Working capital per share of Vyome Holdings, Inc. – MUN:H1O - TradingView
ReShape Lifesciences (OTCMKTS:RSLSD) vs. Vyome (NASDAQ:HIND) Critical Analysis - Defense World
Vyome Holdings Announces Results of Annual Shareholder Meeting - The Joplin Globe
Contrasting ReShape Lifesciences (OTCMKTS:RSLSD) & Vyome (NASDAQ:HIND) - Defense World
Comparing Anzu Special Acquisition Corp I (NASDAQ:ANZUW) & Vyome (NASDAQ:HIND) - Defense World
Vyome Holdings Elects Directors at Annual Meeting - MSN
Vyome Holdings, Inc.Common Stock (Nasdaq:HIND) Stock Quote - Markets Financial Content
Head-To-Head Contrast: Vyome (NASDAQ:HIND) & TranS1 (OTCMKTS:BAXSQ) - Defense World
ReShape Lifesciences : trade; to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate UpdateForm 8-K/A - MarketScreener
Tincoff John M. Iii Net Worth (2025) - GuruFocus
ReShape Lifesciences (OTCMKTS:RSLSD) versus Vyome (NASDAQ:HIND) Financial Survey - Defense World
Will Vyome's Topical Gel Be The First FDA-Approved Treatment For Cancer Wounds? - RTTNews
Head-To-Head Comparison: Vyome (NASDAQ:HIND) vs. Bioventus (NASDAQ:BVS) - Defense World
Head to Head Survey: Vyome (NASDAQ:HIND) versus CapsoVision (NASDAQ:CV) - Defense World
Maxim Group Reaffirms “Buy” Rating for Vyome (NASDAQ:HIND) - Defense World
Vyome Holdings Acquires AI Startup Oculo, Inc. - TipRanks
HIND Analyst Forecasts - Quiver Quantitative
Vyome Holdings acquires Oculo Health - Medical Buyer
Vyome Holdings Acquires MIT Spinout Oculo Health, Launches AI Psychiatrist Business Unit - Sahyadri Startups
Vyome Holdings Acquires MIT AI Spinout Oculo Health - citybiz
Vyome acquires AI startup Oculo to develop inflammation-focused digital therapeutics By Investing.com - Investing.com South Africa
Vyome Holdings Inc Stock (HIND) Financials Data
There is no financial data for Vyome Holdings Inc (HIND). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):